Doxorubicin+cisplatin+ifosfamide+methotrexate

PreclinicalSmall molecule

Doxorubicin+cisplatin+ifosfamide+methotrexate is one of 6 small molecule programs targeting Bone Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone SarcomaActive, not recruiting

Bone SarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Bone Sarcoma

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

—2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 3

Glucophage

EMD Serono

Phase 2

1 4

Zanzalintinib

Merck & Co.

Phase 2

1 5

Adriamycin

Pfizer

Preclinical

—6

Doxorubicin+cisplatin+ifosfamide+methotrexate

IItalian Sarcoma Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Sarcoma1 trial

European Study in Bone Sarcoma Patients Over 40 Years

Completed·IItalian Sarcoma Group··NCT02986503·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxorubicin+cisplatin+ifosfamide+methotrexate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin+cisplatin+ifosfamide+methotrexate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin+cisplatin+ifosfamide+methotrexate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Italian Sarcoma Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IItalian Sarcoma Group

Doxorubicin+cisplatin+ifosfamide+methotrexate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Sarcoma1 trial

References

Drug Info

Quick Facts

Related News